← Leaderboards
Anil Jegga
Cincinnati Childrens Hosp Med Ctr
$689,493
Attributed
$1,476,237
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $435K · FY2016–20$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,476,237 · 4
By mechanism
UG3$636,000 · 1
R21$482,486 · 2
UH3$357,751 · 1
Top collaborators
- Anjaparavanda P Naren3 shared
- John Paul Clancy2 shared
- Satish K Madala2 shared
- Gary Lewis Mcphail1 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- John Joseph Brewington$2,470,821
- Elizabeth L Kramer$820,800
- Zackary I Cleveland$6,645,866
- Assem G Ziady$5,940,444
- Yan Xu$6,358,233
Others in their field
Top investigators on “Novel Therapeutics”
- David Heimbrook · Leidos Biomedical Research, Inc.$355,066,875
- Judith S. Currier · University Of California Los Angeles$321,442,024
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Daniel R Kuritzkes · Brigham And Women'S Hospital$246,024,897
- Sharon A Nachman · Johns Hopkins University$212,395,175
Research focus
Novel TherapeuticsLungBaseCombinatorialScreeningGene ExpressionDesignIn Vitro AssayBiological ModelsProductionTherapeutic CandidateFda ApprovedDoseInnovationBiopsyMalignant NeoplasmsAgreementAnti-InflammatoryClinical TrialsAnti-Infective AgentsBioinformaticsAgarCase Report FormBiochemical
Grant awards (7)
Preclinical characterization of saracatinib for cystic fibrosis therapy$357,751
UH3 · FY2020 · TR · contact PI
Preclinical characterization of saracatinib for cystic fibrosis therapy$318,000
UG3 · FY2019 · TR · contact PI
Preclinical characterization of saracatinib for cystic fibrosis therapy$318,000
UG3 · FY2018 · TR · contact PI
Discovery and characterization of candidate therapeutics for drug-induced pulmonary disease$117,000
R21 · FY2018 · HL · contact PI
Integrative analysis of multi-omics data to target fibroblast activation in IPF$120,627
R21 · FY2017 · HL
Discovery and characterization of candidate therapeutics for drug-induced pulmonary disease$117,000
R21 · FY2017 · HL · contact PI
Integrative analysis of multi-omics data to target fibroblast activation in IPF$127,859
R21 · FY2016 · HL